A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

NCT03713658 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Risperidone 3 mg
DRUG: Paliperidone Palmitate 50 mg eq.
DRUG: Paliperidone Palmitate 75 mg eq.
DRUG: Paliperidone Palmitate 100 mg eq.
DRUG: Paliperidone Palmitate 150 mg eq.
DRUG: Paliperidone Palmitate 175 mg eq.
DRUG: Paliperidone Palmitate 263 mg eq.
DRUG: Paliperidone Palmitate 350 mg eq.
DRUG: Paliperidone Palmitate 525 mg eq.

Sponsor

Janssen Research & Development, LLC